[57] The CDK4 inhibitor, palbociclib, also had contradicting evidence regarding blood-brain barrier penetration, [58] and tumor board discussions of preliminary data of the GBM clinical trial of palbociclib, later terminated, revealed that the physicians were less likely to recommend this drug. The gene discussed is CDK4; the disease is glioblastoma.